---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004975"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:06:22.330131+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos reports Q2 net loss $18.8M; cash $90.8M; NASH program on track for Q4 Phase 2a filing

## Summary
- Net loss $18.8M ($0.43/shr) vs $19.9M ($0.47) in Q2 2022.
- Cash $90.8M at June 30, 2023, down from $125.8M; sufficient through end 2024.
- NASH candidate ALG-055009 Phase 1 complete; Phase 2a protocol filing expected Q4 2023; topline data Q4 2024.
- COVID-19 protease inhibitor ALG-097558: first-in-human dosing ongoing; topline data H1 2024.
- Agreement in principle with Janssen to resolve litigation; case stayed July 31, 2023.

## SEC filing metadata
- accession: 0001171843-23-004975
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/0001171843-23-004975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/f8k_080323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004975
- JSON: https://secwatch.observer/filing/0001171843-23-004975.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004975.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported three months ended June 30, 2023 results: net income $18.8 million, EPS $(0.43).
  - Period: three months ended June 30, 2023
  - Net income: $18.8 million
  - EPS: $(0.43)
  - Result: reported results
  source text: Net losses for the three months ended June 30, 2023, were $18.8 million or basic and diluted net loss per common share of $(0.43), compared to net losses of $19.9 million or basic and diluted net loss per common share of $(0.47) for the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/0001171843-23-004975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.